Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - April 20, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMN24 IsKia study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients March 2, 2020 Epigenetic Changes Pinpointed as the Cause of Some GISTs November 19, 2019 Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... June 4, 2025 EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... November 8, 2021 Load more HOT NEWS FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and... How Wartime Violence Against Women Is Hurting Millions Worldwide
